Peptide Schedule
Bonothyrk6 residuesAEDLRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Bonothyrk
Benefits
About Bonothyrk
Bonothyrk is a bovine-derived peptide bioregulator containing a standardized extract of polypeptides from the parathyroid glands of young animals. Designated as Peptide Complex A-21, it was developed by Professor Vladimir Khavinson's research group at the St. Petersburg Institute of Bioregulation and Gerontology as part of a broader program that produced over 20 tissue-specific bioregulators over four decades of research. The preparation targets parathyroid gland cells with the goal of normalizing intracellular metabolism and restoring the gland's ability to properly regulate calcium homeostasis. Khavinson's bioregulatory theory proposes that short peptides (2-7 amino acid residues) can penetrate cell nuclei, interact with specific promoter regions of DNA, and modulate gene expression through epigenetic mechanisms including DNA methylation status changes. When applied to parathyroid tissue, this is thought to restore age-related declines in parathyroid hormone (PTH) regulation, helping maintain normal blood calcium and phosphorus levels. One clinical observation tracked 33 perimenopausal women aged 47-56 with high osteoporosis risk who received Bonothyrk (two capsules twice daily for 30 days). The treated group showed measurable improvements in bone mineral density parameters compared to controls. It's worth noting that published evidence specific to Bonothyrk remains limited and is largely confined to Russian-language medical literature. No peer-reviewed PubMed-indexed studies focus exclusively on this preparation. The broader class of Khavinson bioregulators has been studied more extensively, but most Western researchers haven't independently replicated the parathyroid-specific findings.
Who Should Consider Bonothyrk
- Perimenopausal and postmenopausal women at risk of osteoporosis
- Older adults with age-related parathyroid gland decline
- Individuals with suboptimal calcium metabolism markers
- Patients recovering from parathyroid surgery or dysfunction
- People with recurrent muscle cramps linked to calcium imbalance
- Those seeking preventive support for bone mineral density maintenance
How Bonothyrk Works
Bonothyrk's proposed mechanism follows the Khavinson bioregulatory model, in which short-chain peptides extracted from target tissue interact with gene regulatory elements to restore tissue-specific protein synthesis. The parathyroid-derived peptide fragments (primarily 2-7 amino acid residues in length) are thought to cross cell membranes and enter the nuclei of parathyroid chief cells, where they bind to complementary sequences in gene promoter regions. This interaction is believed to modulate RNA polymerase activity and trigger transcription of proteins involved in parathyroid hormone (PTH) synthesis and secretion. At the epigenetic level, these peptides may influence DNA methylation patterns, shifting gene expression toward a younger, more functional state. This could restore the calcium-sensing receptor (CaSR) sensitivity that typically declines with age, allowing parathyroid cells to respond more accurately to fluctuations in blood calcium levels. The downstream effect would be better-regulated PTH release, which in turn governs calcium reabsorption in the kidneys, calcium release from bone, and vitamin D activation for intestinal calcium absorption. However, these mechanisms are largely theoretical and extrapolated from general Khavinson peptide research rather than demonstrated specifically for Bonothyrk in published controlled studies.
What to Expect
No noticeable effects expected. The peptide complex begins interacting with parathyroid cells at the gene expression level. Some users report reduced frequency of muscle cramps.
Subtle improvements in calcium-related symptoms may begin. Reduced muscle spasms and cramping have been reported anecdotally. Gene expression changes are believed to be underway.
Full course effects should be building. Clinical observations suggest measurable improvements in bone mineral density markers by the end of a 30-day course, though individual results vary widely.
Benefits are thought to persist for several months after completing a course due to sustained gene expression changes in parathyroid tissue. This is the rationale for the 4-6 month gap between courses.
Cumulative benefits with repeated courses are reported in Khavinson bioregulator literature. Bone density and calcium metabolism parameters may show progressive improvement across multiple treatment cycles.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 10mg | 2x Daily |
| Aggressive | 20mg | 2x Daily |
Note: Bonothyrk (A-21) is a natural peptide bioregulator derived from the parathyroid glands of young cattle. It belongs to the Khavinson class of cytomedins — tissue-specific polypeptide fractions developed at the St. Petersburg Institute of Bioregulation and Gerontology. Capsules typically contain 10 mg of the parathyroid peptide complex. Because it's a complex mixture of short-chain peptides rather than a single defined molecule, precise pharmacokinetic data for individual components isn't available. Standard protocols call for 1-2 capsules taken 1-2 times daily with meals over a 30-day course, repeated 2-3 times per year.
How to Inject Bonothyrk
Take 1-2 capsules orally with meals, 1-2 times daily. The standard adult protocol is 2 capsules twice daily (total 40 mg/day) for 30 consecutive days. For maintenance, a lower dose of 1 capsule daily may be used. Swallow capsules whole with water — don't crush or open them. Morning and early afternoon dosing is generally recommended to align with the body's natural calcium regulation rhythms. A sublingual (lingual) version is also available for those who prefer buccal absorption. Don't take on an empty stomach to minimize gastrointestinal discomfort. Monitor blood calcium levels periodically during use, especially if you have pre-existing parathyroid conditions.
Cycling Protocol
Standard Khavinson protocol: 30-day course of daily oral capsules, repeated 2-3 times per year with 4-6 month intervals between courses. Some practitioners recommend an initial loading phase of two courses with a 1-month break in between for individuals with significant parathyroid or calcium metabolism concerns.
Pharmacokinetics
Source: Estimated from general polypeptide fraction kinetics; no Bonothyrk-specific PK studies published (Khavinson & Anisimov, 2010)
Loading the interactive decay curve.
Side Effects
Bonothyrk is generally well tolerated based on available reports from clinical use in Russia and CIS countries. The most commonly noted side effects are mild gastrointestinal discomfort, including nausea or stomach upset when taken without food. Allergic reactions are possible given the bovine-derived origin of the peptide complex, and individuals with known sensitivities to animal proteins should exercise caution. Headache and mild dizziness have been reported occasionally. Because the preparation influences calcium metabolism, individuals with pre-existing hypercalcemia or hypocalcemia should use it only under medical supervision. Theoretical concerns about prion contamination exist with any bovine-derived brain or glandular tissue product, though no cases have been reported. Long-term safety data from controlled studies isn't publicly available in English-language literature.
Contraindications
- Pregnancy and breastfeeding (no safety data available)
- Known hypersensitivity to bovine-derived glandular products
- Hypercalcemia or conditions causing elevated blood calcium
- Primary hyperparathyroidism (overactive parathyroid glands)
- Children under 14 years of age
- Severe renal impairment affecting calcium excretion
Drug Interactions
- Use caution with calcium supplements — additive effects on blood calcium levels possible
- May interact with vitamin D supplementation by altering calcium absorption dynamics
- Bisphosphonates and other osteoporosis medications — theoretical interaction through overlapping calcium pathways
- Thiazide diuretics can raise calcium levels and may compound effects
- Lithium can affect parathyroid function and may interact unpredictably
- No formal drug interaction studies have been published for Bonothyrk specifically
Storage & Stability
Molecular Profile
Related Peptides
References
- Peptide bioregulation of aging: results and prospectsPubMed 19830585
- Peptide regulation of aging: 35-year research experiencePubMed 19902107
- Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studiesPubMed 23734519
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies resultsPubMed 24003726
- Peptide Regulation of Gene Expression: A Systematic ReviewPubMed 34834147
- Peptide Regulation of Cell DifferentiationPubMed 31808038